A new report on the issues around access to innovative medicines in New Zealand was launched at Parliament on March 3rd by Deputy Prime Minister David Seymour, hosted by ACT MP Todd Stephenson. This was attended by several patient group representatives including Fiona Imlach from Migraine Foundation Aotearoa New Zealand.
The report was based on a review of the current medicines landscape in New Zealand, including documents, papers and legislative framework, and consultation with patient groups.
Five key priority areas were identified:
- Expand the pharmaceutical budget
- Improve transparency and engagement
- Modernise Pharmac processes
- Prioritise health equity
- Enhance national productivity.
All of the recommendations from these priorities are relevant to those of us with migraine who want better access to new treatments that are safer, more effective and improve quality of life.
Yes, we want more investment in medicines and health, and recognition that this investment is critical to support people to be engaged in life and productive at work. Yes, we want clearer information and input into decisions about the funding of medicines.
Yes, we want timely responses from Pharmac and proactive identification and assessment of new and emerging treatments. Yes, we want Māori, Pacific and underserved communities to have improved access to treatment and improved health outcomes. And yes, we want medicines that keep us out of ED and hospital and mean we can work, play and live life to our full potential.
That this report was launched at Parliament is an encouraging sign. This is a topic that politicians are taking an interest in. This is a question to ask of all MPs during election year: What will you do to increase access to medicines that will improve the health and well-being of New Zealanders?
The report was commissioned by Bristol Myers Squibb Australia: Access to Innovative Pharmaceutical Medicines in New Zealand (report)
